PerSe Technologies News

Pluristem Therapeutics, Inc . , today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a NIS 9 million grant from the Office of the Chief Scientist within the Israeli Ministry of Industry, Trade and Labor.

The stock last traded at $2.51, down from its previous close of $2.54. Separately, analysts at Global Hunter Securities initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Friday, December 9th.

HAIFA, Israel, Nov. 22, 2011 -- Dear Shareholders, As we close in on the end of the calendar year, it is important to look back upon all that we at Pluristem have accomplished over the last 12 months, but it is even more crucial to focus the majority of our energies on the challenges and opportunities awaiting Pluristem Therapeutics in 2012 and ... (more)

Pluristem Therapeutics, Inc . today announced positive 12-month data from its Phase I open-label, dose-escalation clinical trials conducted under protocols approved by the Food & Drug Administration in the USA and the Paul-Ehrlich-Institute in Germany.

Are you convinced that Cell Therapy is a viable process which can be used to treat diseases? Lonza AG is.